FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

International Journal of Cardiology

Volumn 202, Issue , 2016, Pages 52-58

  Berger, Rolf M F ^a   Haworth, Sheila G ^b   Bonnet, Damien ^c   Dulac, Yves ^d   Fraisse, Alain ^e   Galiè, Nazzareno ^f   Ivy, D Dunbar ^g   Jaïs, Xavier ^h   Miera, Oliver ⁱ   Rosenzweig, Erika B ^j   Efficace, Michela ^k   Kusic Pajic, Andjela ^l   Beghetti, Maurice ^m  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL DES ENFANTS   (France)

^e TIMONE HOSPITAL   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g CHILDREN S HOSPITAL   (United States)

^h BICÊTRE HOSPITAL   (France)

ⁱ DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k Actelion Pharmaceuticals Italia Srl   (Italy)

^l ACTELION PHARMACEUTICALS LTD   (Switzerland)

^m UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

Bosentan; Pediatric; Pulmonary arterial hypertension; Safety

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BOSENTAN; DIGOXIN; F ACTIN ANTIBODY; FUROSEMIDE; HEMOGLOBIN; IMMUNOGLOBULIN G; LIVER ENZYME; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROTEIN ANTIBODY; SILDENAFIL; UNCLASSIFIED DRUG; WARFARIN; ENDOTHELIN RECEPTOR ANTAGONIST; PHARMACOLOGICAL BIOMARKER; SULFONAMIDE;

ABDOMINAL PAIN; ADENOIDECTOMY; ARTERIAL SEPTOSTOMY; ARTERY CATHETERIZATION; ARTICLE; AUTOIMMUNE HEPATITIS; BACTEREMIA; BALLOON CATHETERIZATION; BRONCHITIS; BRONCHUS OBSTRUCTION; CELLULITIS; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COUGHING; DEVICE INFECTION; DIAPHRAGM HERNIA; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EAR INFECTION; FAINTNESS; FATIGUE; FEMALE; FLANK PAIN; FLUSHING; HEADACHE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HERITABILITY; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INJECTION SITE NODULE; IRON DEFICIENCY ANEMIA; KAPLAN MEIER METHOD; LOBAR PNEUMONIA; LUNG ARTERY PRESSURE; LUNG INFECTION; MALE; MEDICAL DEVICE COMPLICATION; MONOTHERAPY; MORTALITY; OPEN STUDY; PEDIATRICS; PERICARDIAL EFFUSION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VEIN OBSTRUCTION; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; SURGICAL INFECTION; SURVIVAL TIME; THORAX PAIN; TREATMENT DURATION; TUBERCULOUS SPONDYLITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WHEEZING; ADULT; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERANCE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FOLLOW UP; HEALTH; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; ADULT; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENDOTHELIN RECEPTOR ANTAGONISTS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; MALE; SULFONAMIDES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960086357     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.080     Document Type: Article

References (30)

1. M.M. Hoeper, H.J. Bogaard, R. Condliffe, and et al. Definitions and diagnosis of pulmonary hypertension J. Am. Coll. Cardiol. 62 25 Suppl. 2013 D42 D50
2. R.J. Barst, S.I. Ertel, M. Beghetti, and D.D. Ivy Pulmonary arterial hypertension: a comparison between children and adults Eur. Respir. J. 37 2011 665 677
3. D.B. Badesch, H.C. Champion, M.A. Sanchez, and et al. Diagnosis and assessment of pulmonary arterial hypertension J. Am. Coll. Cardiol. 54 1 Suppl 2009 S55 S66
4. D.D. Ivy, S.H. Abman, R.J. Barst, and et al. Pediatric pulmonary hypertension J. Am. Coll. Cardiol. 62 25 Suppl 2013 D117 D126
5. R.M.F. Berger, M. Beghetti, T. Humpl, and et al. Clinical features of paediatric pulmonary hypertension: a registry study Lancet 379 2012 537 546
6. M.D. McGoon, and D.P. Miller REVEAL: a contemporary US pulmonary arterial hypertension registry Eur. Respir. Rev. 21 2012 8 18
7. R.J. Barst, M.D. McGoon, C.G. Elliott, A.J. Foreman, D.P. Miller, and D.D. Ivy Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management Circulation 125 2012 113 122
8. W.M.H. Zijlstra, J.M. Douwes, E.B. Rosenzweig, and et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies J. Am. Coll. Cardiol. 63 2014 2159 2169
9. R.L. van Loon, M.T.R. Roofthooft, H.L. Hillege, and et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005 Circulation 124 2011 1755 1764
10. S.G. Haworth, and A.A. Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart 95 2009 312 317
11. A. Manes, M. Palazzini, E. Leci, M.L. Bacchi Reggiani, A. Branzi, and N. Galiè Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups Eur. Heart J. 35 2014 716 724
12. I. Adatia, S.G. Haworth, M. Wegner, and et al. Clinical trials in neonates and children: report of the pulmonary hypertension academic research consortium pediatric advisory committee Pulm. Circ. 3 2013 252 266
13. E.B. Rosenzweig, D.D. Ivy, A. Widlitz, and et al. Effects of long-term bosentan in children with pulmonary arterial hypertension J. Am. Coll. Cardiol. 46 2005 697 704
14. S. Maiya, A.A. Hislop, Y. Flynn, and S.G. Haworth Response to bosentan in children with pulmonary hypertension Heart 92 2006 664 670
15. A.A. Hislop, S. Moledina, H. Foster, I. Schulze-Neick, and S.G. Haworth Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Eur. Respir. J. 38 2011 70 77
16. R.L. van Loon, E.S. Hoendermis, M.G.J. Duffels, A. Vonk-Noordegraaf, B.J.M. Mulder, H.L. Hillege, and R.M.F. Berger Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am. Heart J. 154 2007 776 782
17. R.J. Barst, D. Ivy, J. Dingemanse, and et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin. Pharmacol. Ther. 73 2003 372 382
18. M. Beghetti, S.G. Haworth, D. Bonnet, and et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study Br. J. Clin. Pharmacol. 68 2009 948 955
19. ICH Harmonised Tripartite Guideline Clinical safety data management: definitions and standards for expedited reporting E2A Version 27 October 1994. Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html (Accessed 26 May 2015)
20. R.M.F. Berger Pulmonary hypertension: smaller kids, smaller steps Lancet Respir. Med. 2 2014 348 350
21. R.N. Channick, G. Simonneau, O. Sitbon, and et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
22. L.J. Rubin, D.B. Badesch, R.J. Barst, and et al. Bosentan therapy for pulmonary arterial hypertension N. Engl. J. Med. 346 2002 896 903
23. N. Galiè, L. Rubin, M. Hoeper, and et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
24. D.D. Ivy, E.B. Rosenzweig, J.C. Lemarié, M. Brand, D. Rosenberg, and R.J. Barst Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings Am. J. Cardiol. 106 2010 1332 1338
25. M. Beghetti, M.M. Hoeper, D.G. Kiely, J. Carlsen, B. Schwierin, E.S. Segal, and M. Humbert Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program Pediatr. Res. 64 2008 200 204
26. R.L. van Loon, M.T.R. Roofthooft, T. Delhaas, and et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies Am. J. Cardiol. 106 2010 117 124
27. G.E. D'Alonzo, R.J. Barst, S.M. Ayres, and et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann. Intern. Med. 115 1991 343 349
28. R.J. Barst, G. Maislin, and A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197 1208
29. J. Sandoval, O. Bauerle, A. Gomez, A. Palomar, M.L. Martínez Guerra, and M.E. Furuya Primary pulmonary hypertension in children: clinical characterization and survival J. Am. Coll. Cardiol. 25 1995 466 474
30. M. Beghetti Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs Eur. Respir. Rev. 18 2009 18 23